Stoke Therapeutics (NASDAQ:STOK) Upgraded to “Outperform” by TD Cowen

TD Cowen upgraded shares of Stoke Therapeutics (NASDAQ:STOK) from a market perform rating to an outperform rating in a report published on Tuesday, Marketbeat Ratings reports.

Several other equities research analysts have also commented on the stock. JPMorgan Chase & Co. raised their price target on shares of Stoke Therapeutics from $6.00 to $13.00 and gave the company a neutral rating in a research note on Tuesday. Needham & Company LLC reiterated a buy rating and issued a $14.00 price objective on shares of Stoke Therapeutics in a report on Friday, February 16th. Finally, Canaccord Genuity Group increased their price objective on shares of Stoke Therapeutics from $18.00 to $21.00 and gave the company a buy rating in a report on Tuesday. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Stoke Therapeutics currently has a consensus rating of Moderate Buy and a consensus price target of $19.63.

Stoke Therapeutics Trading Down 4.7 %

Shares of NASDAQ:STOK opened at $13.50 on Tuesday. The firm’s 50 day moving average is $6.24 and its two-hundred day moving average is $5.08. Stoke Therapeutics has a 52 week low of $3.35 and a 52 week high of $16.40. The firm has a market capitalization of $625.05 million, a P/E ratio of -5.70 and a beta of 0.68.

Insider Buying and Selling

In related news, insider Barry Ticho sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $5.74, for a total transaction of $57,400.00. Following the completion of the sale, the insider now directly owns 16,981 shares in the company, valued at $97,470.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, insider Barry Ticho sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $5.74, for a total value of $57,400.00. Following the completion of the transaction, the insider now owns 16,981 shares of the company’s stock, valued at approximately $97,470.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Stephen J. Tulipano sold 4,116 shares of the firm’s stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total transaction of $25,107.60. Following the completion of the transaction, the chief financial officer now directly owns 20,746 shares of the company’s stock, valued at approximately $126,550.60. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 37,615 shares of company stock worth $212,852. Corporate insiders own 12.30% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

A number of institutional investors have recently modified their holdings of STOK. Swiss National Bank boosted its stake in shares of Stoke Therapeutics by 8.2% during the 1st quarter. Swiss National Bank now owns 30,500 shares of the company’s stock valued at $642,000 after buying an additional 2,300 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Stoke Therapeutics by 20.8% during the 1st quarter. JPMorgan Chase & Co. now owns 19,608 shares of the company’s stock valued at $412,000 after buying an additional 3,374 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Stoke Therapeutics by 1.4% during the 1st quarter. Bank of New York Mellon Corp now owns 62,698 shares of the company’s stock valued at $1,320,000 after buying an additional 837 shares during the period. MetLife Investment Management LLC boosted its stake in shares of Stoke Therapeutics by 58.5% during the 1st quarter. MetLife Investment Management LLC now owns 11,621 shares of the company’s stock valued at $245,000 after buying an additional 4,289 shares during the period. Finally, Rhumbline Advisers boosted its stake in shares of Stoke Therapeutics by 7.6% during the 1st quarter. Rhumbline Advisers now owns 19,345 shares of the company’s stock valued at $407,000 after buying an additional 1,362 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.